← Oncology Approval Tracker

FDA DECISION ·

Rybrevant

amivantamab-vmjw · Janssen Biotech

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Mar 1, 2024

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations on an FDA-approved test, after progression during or after platinum chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The accelerated decision adds a targeted antibody in post-platinum EGFR exon 20 insertion disease. FDA later converted the indication on March 1, 2024.

What research teams should watch

Capture the exact insertion class and platinum history and plan monitoring for infusion reactions.

PRIMARY RECORDS

Sources